Insider John P. Schmid Sells 12,596 Shares of AnaptysBio at a Bull‑Market Premium, Signals Confidence in Upward Trajectory

Insider Selling in a Bull‑Market Context

AnaptysBio’s most recent Form 4, filed by director John P. Schmid on March 30, 2026, reports the sale of 12,596, 7,527 and 522 common shares for an average price of $56.71—just above the closing price of $55.46. The transaction was executed in three separate tranches, each with a slightly higher weighted average price, suggesting Schmid was willing to capture incremental gains as the stock climbed toward its 52‑week high of $68.39. The sale, which reduced his holdings from 39,671 to 31,622 shares, came at a time when market sentiment for AnaptysBio was markedly positive (+10 on social media) and buzz was 11.23 %—well above the normal 100 % intensity. In other words, investors were already primed to trade on the news, and Schmid’s exit did not trigger a significant sell‑off.

Implications for Investors and the Company’s Future

Schmid’s divestiture is modest relative to his 52‑week average share ownership of roughly 45,000 shares. With the company’s market cap at $1.59 billion and a negative earnings‑per‑share figure, the sale does not signal an immediate liquidity crunch or loss of confidence. Instead, it may reflect a personal portfolio rebalancing by an insider who has already benefited from the share‑buyback program and the recent “buy” recommendation from HC Wainwright. For investors, the key takeaway is that AnaptysBio’s insiders are still net holders and that the company’s fundamentals—strong quarterly results and a pipeline of antibody candidates—continue to attract institutional buying. The timing of the sale, amid rising sentiment and buzz, suggests that insiders are confident in the stock’s upside and are capitalizing on a temporary price premium rather than anticipating a downturn.

John P. Schmid: A Transaction Profile

Schmid’s transaction history paints the picture of a seasoned insider who prefers to accumulate first and sell later. Beginning in early 2026, he purchased 4,000 restricted stock units and 5,500 stock options, followed by a sizable purchase of 11,068 common shares on December 23, 2025. He then sold the same 11,068 shares a week later, illustrating a pattern of short‑term speculation. His most recent sale on March 30, 2026, is part of a broader trend of insider sales by senior executives—including President CEO Daniel Faga, who has sold over 25,000 shares in the same week—yet insiders collectively remain net long. Schmid’s activity indicates a willingness to trade in liquidity‑constrained environments while still maintaining a significant stake, a balance that may appeal to value‑oriented investors.

Key Takeaway for Market Participants

For traders and long‑term holders, Schmid’s March 30 sale is a signal of insider confidence rather than alarm. The company’s positive earnings momentum, coupled with a robust share‑buyback, supports a narrative of undervaluation that is already reflected in the price. Insider selling, when isolated and small, can actually reinforce the idea that insiders are not facing immediate cash needs and are comfortable taking profits at a price that is already above the 52‑week low. As AnaptysBio moves forward with its antibody pipeline, the remaining insider holdings and institutional support suggest that the stock may continue to trade in the upside range, provided that clinical milestones are met and the market sustains its bullish sentiment.